The authors wish to make the following corrections to this paper [1]:
Please note that Midwestern University signed the technology transfer agreement very recently, this is the reason why we forgot to modify the conflict of interest statement in the last revision of the manuscript.
The “Conflicts of Interest” statement should be changed to:
Conflicts of Interest: M.J.O. is the CEO of Crenae Therapeutics which has licensed ASPH inhibitor technologies from Midwestern University. The other authors declare no conflict of interest.
The authors would like to apologize for any inconvenience caused to the readers by these changes.
Reference
- 1.Benelli R., Costa D., Mastracci L., Grillo F., Olsen M.J., Barboro P., Poggi A., Ferrari N. Aspartate-β-Hydroxylase: A Promising Target to Limit the Local Invasiveness of Colorectal Cancer. Cancers. 2020;12:971. doi: 10.3390/cancers12040971. [DOI] [PMC free article] [PubMed] [Google Scholar]